Adalimumab
Adalimumab (pronounced as a-dal-i-mu-mab) is a biopharmaceutical drug used primarily to treat autoimmune diseases. It is a monoclonal antibody that works by blocking tumor necrosis factor alpha (TNF-alpha), a substance in the body that causes inflammation.
Etymology
The name "Adalimumab" is derived from the parts: "ada-" from human, "-lim-" from immunoglobulin (Ig), "-u-" from human, and "-mab" meaning monoclonal antibody.
Usage
Adalimumab is used to treat various autoimmune diseases including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis. It is also used in the treatment of juvenile idiopathic arthritis in children.
Mechanism of Action
Adalimumab binds specifically to tumor necrosis factor alpha (TNF-alpha) and blocks its interaction with the p55 and p75 cell surface TNF receptors. This results in the reduction of the inflammatory response which is a characteristic of autoimmune diseases.
Side Effects
Common side effects of Adalimumab include infection, injection site reactions, headache, and rash. Serious side effects may include tuberculosis, sepsis, and other infections, lymphoma, and autoimmune disorders.
Related Terms
- Monoclonal antibody
- Autoimmune disease
- Tumor necrosis factor alpha
- Rheumatoid arthritis
- Psoriatic arthritis
- Ankylosing spondylitis
- Crohn's disease
- Ulcerative colitis
- Plaque psoriasis
- Hidradenitis suppurativa
- Uveitis
- Juvenile idiopathic arthritis
External links
- Medical encyclopedia article on Adalimumab
- Wikipedia's article - Adalimumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski